Heparanase inhibition prevents glycocalyx damage and albuminuria in experimental minimal change disease

Michael Crompton; Raina D. Ramnath; Kai Betteridge; Sara Desideri; Aldara Martin Alonso; Lulu Jiang; Monica Gamez; Holly Stowell-Connolly; Viktoriia Vasylchenko; Karen L. Onions; Matthew J. Butler; Chris R. Neal; Andrew H. J. Salmon; Jeremy E. Turnbull; Hiroshi Kawachi; Olga V. Zubkova; Gavin I. Welsh; Simon C. Satchell; Rebecca R. Foster

doi:10.1002/ctm2.70706

Clinical and Translational Medicine ›› 2026, Vol. 16 ›› Issue (6) :e70706 DOI: 10.1002/ctm2.70706

LETTER TO THE JOURNAL

Heparanase inhibition prevents glycocalyx damage and albuminuria in experimental minimal change disease

Author information +

History +

PDF (1543KB)

Cite this article

Download citation ▾

Michael Crompton, Raina D. Ramnath, Kai Betteridge, Sara Desideri, Aldara Martin Alonso, Lulu Jiang, Monica Gamez, Holly Stowell-Connolly, Viktoriia Vasylchenko, Karen L. Onions, Matthew J. Butler, Chris R. Neal, Andrew H. J. Salmon, Jeremy E. Turnbull, Hiroshi Kawachi, Olga V. Zubkova, Gavin I. Welsh, Simon C. Satchell, Rebecca R. Foster. Heparanase inhibition prevents glycocalyx damage and albuminuria in experimental minimal change disease. Clinical and Translational Medicine, 2026, 16 (6) : e70706 DOI:10.1002/ctm2.70706

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Roman M, Nowicki M. Detailed pathophysiology of minimal change disease: insights into podocyte dysfunction, immune dysregulation, and genetic susceptibility. Int J Mol Sci. 2024; 25:12174.

[2]	Rout P, Hashmi MF, Baradhi KM. Focal Segmental Glomerulosclerosis. StatPearls Publishing LLC; 2025.

[3]	Purohit S, Piani F, Ordoñez FA, de Lucas-Collantes C, Bauer C, Cara-Fuentes G. Molecular mechanisms of proteinuria in minimal change disease. Front Med (Lausanne). 2021; 8:761600.

[4]	Garsen M, Lenoir O, Rops AL, et al. Endothelin-1 induces proteinuria by heparanase-mediated disruption of the glomerular glycocalyx. J Am Soc Nephrol. 2016; 27: 3545-3551.

[5]	Bauer C, Piani F, Banks M, et al. Minimal change disease is associated with endothelial glycocalyx degradation and endothelial activation. Kidney Int Rep. 2022; 7: 797-809.

[6]	Zubkova OV, Ahmed YA, Guimond SE, et al. Dendrimer heparan sulfate glycomimetics: potent heparanase inhibitors for anticancer therapy. ACS Chem Biol. 2018; 13: 3236-3242.

[7]	Orikasa M, Matsui K, Oite T, Shimizu F. Massive proteinuria induced in rats by a single intravenous injection of a monoclonal antibody. J Immunol. 1988; 141: 807-814.

[8]	Watts AJB, Keller KH, Lerner G, et al. Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J Am Soc Nephrol. 2022; 33: 238-252.

[9]	Gamez M, Elhegni HE, Fawaz S, et al. Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes. Cardiovasc Diabetol. 2024; 23: 50.

[10]	Crompton M, Ferguson JK, Ramnath RD, et al. Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx. JCI Insight. 2023; 8(5):e154164.

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.